natgillin/translations-raw huggingface dataset:
Compared with tiotropium, Trydonis improved pre-dose FEV1 by 51 mL after 26 weeks of treatment and by 61 mL after 52 weeks of treatment. 
V primerjavi s tiotropijem je zdravilo Trydonis izboljšalo FEV1 pred odmerkom za 51 ml po 26-tedenskem zdravljenju in za 61 ml po 52-tedenskem zdravljenju.
• if you experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes. 
zlasti v predelu oči, obraza, ustnic in žrela; • če opazite bolečino ali težave z očesom, začasno zamegljen vid, očesne kolobarje ali barvne slike, povezane s pordelim očesom.
Immediate hypersensitivity reactions have been reported after administration of Trydonis. 
Preobčutljivost Po jemanju zdravila Trydonis so poročali o takojšnjih preobčutljivostnih reakcijah.
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis significantly improved 2-hour post dose FEV1 by 117 mL after 26 weeks of treatment and by 103 mL after 52 weeks of treatment (p < 0.001). 
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trydonis značilno izboljšalo FEV1 2 uri po odmerku za 117 ml po 26-tedenskem zdravljenju in za 103 ml po 52-tedenskem zdravljenju (p < 0,001).
• inflammation of the sinuses 
• gripa; • vnetje sinusov;
Beclometasone dipropionate given by inhalation at recommended doses has a glucocorticoid antiinflammatory action within the lungs. 
V priporočenih odmerkih inhalirani beklometazondipropionat deluje v pljučih glukokortikoidno protivnetno.
Compared with a fixed combination of indacaterol and glycopyrronium, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 15% (rate: 0.50 versus 0.59 events per patient/year; p = 0.043). 
V primerjavi s fiksno kombinacijo indakaterola in glikopironija je zdravilo Trydonis v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 15 % (razmerje: 0,50 v primerjavi z 0,59 dogodka na bolnika/leto; p = 0,043).
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis improved pre-dose FEV1 by 81 mL after 26 weeks of treatment and by 63 mL after 52 weeks of treatment. 
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trydonis izboljšalo FEV1 pred odmerkom za 81 ml po 26-tedenskem zdravljenju in za 63 ml po 52-tedenskem zdravljenju.
Trydonis is a pressurised inhalation, solution. 
Zdravilo Trydonis je inhalacijska raztopina pod tlakom.
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 23% (rate: 0.41 versus 0.53 events per patient/year; p = 0.005). 
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trydonis v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 23 % (razmerje: 0,41 v primerjavi z 0,53 dogodka na bolnika/leto; p = 0,005).
It is important that you take your dose as advised by your doctor. 
Če ste uporabili večji odmerek zdravila Trydonis, kot bi smeli Pomembno je, da uporabite odmerek, ki vam ga je svetoval zdravnik.
Trydonis significantly improved dyspnoea (measured as the Transition Dyspnoea Index - TDI - focal score) after 26 weeks of treatment compared with baseline (by 1.71 units; p < 0.001), but the adjusted mean difference versus a fixed combination of beclometasone dipropionate and formoterol was not statistically significant (0.21 units; p = 0.160). 
p < 0,001), vendar prilagojena srednja razlika v primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola ni bila statistično značilna (0,21 enot; p = 0,160).
Compared with tiotropium, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 20% (rate: 0.46 versus 0.57 events per patient/year; p = 0.003). 
V primerjavi s tiotropijem je zdravilo Trydonis v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 20 % (razmerje: 0,46 v primerjavi z 0,57 dogodka na bolnika/leto; p = 0,003).
Use of Trydonis in patients with severe renal impairment or end-stage renal disease requiring dialysis, especially if associated with significant body weight reduction, should be considered only if the expected benefit outweighs the potential risk (see section 4.4 and section 5.2). 
ki zahteva dializno zdravljenje, zlasti v povezavi s pomembnim zmanjšanjem telesne mase, je možna le, če so pričakovane koristi večje od možnih tveganj (glejte poglavje 4.4 in poglavje 5.2).
Trydonis should be used with caution in patients with cardiac arrhythmias, especially third degree atrioventricular block and tachyarrhythmias (accelerated and/or irregular heart beat), idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease (particularly acute myocardial infarction, ischaemic heart disease, congestive heart failure), occlusive vascular diseases (particularly arteriosclerosis), arterial hypertension and aneurysm. 
idiopatsko subvalvularno aortno stenozo, hipertrofično obstruktivno kardiomiopatijo, hudo boleznijo srca (zlasti akutni miokardni infarkt, ishemična bolezen srca, kongestivno srčno popuščanje),
The study compared data obtained after treatment with a single dose of Trydonis (4 inhalations of 100/6/25 micrograms, a non-marketed formulation containing twice the approved strength of glycopyrronium) or a single dose of the extemporary combination of beclometasone dipropionate/formoterol (4 inhalations of 100/6 micrograms) plus glycopyrronium (4 inhalations of 25 micrograms). 
100/6/25 mikrogramov, s formulacijo, ki je ni na trgu n ki vsebuje dvakratno odobreno jakost glikopironija) ali enkratnim odmerkom trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola 100/6 mikrogramov (4 inhalacije po 100/6 mikrogramov)
Trydonis 87/5/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium 
Trydonis 87/5/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
TRISTAR was a 26-week active-controlled open label study comparing Trydonis with an extemporary combination made of a fixed combination of fluticasone/vilanterol 92/22 micrograms inhalation powder, one inhalation once daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (1,157 randomised patients). 
Trydonis s kombinacijo, sestavljeno iz fiksne kombinacije flutikazona/vilanterola 92/22 mikrogramov prašek za inhaliranje, ena inhalacija enkrat na dan plus tiotropij 18 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (1.157 randomiziranih bolnikov).
• fungal infections of the chest 
• glivične okužbe prsnega koša;
Package leaflet: Information for the user Trydonis 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium 
Navodilo za uporabo Trydonis 87 mikrogramov/5 mikrogramov/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
If you have been using a different inhaler containing beclometasone dipropionate previously, ask your doctor for advice, as the effective dose of beclometasone dipropionate in Trydonis for the treatment of COPD may be lower than that of some other inhalers. 
saj je učinkoviti odmerek beklometazondipropionata v zdravilu Trydonis za zdravljenje KOPB morda manjši kot v nekaterih drugih inhalatorjih.
• flu 
• nemir;
In addition, compared with both a fixed combination of beclometasone dipropionate and formoterol and with tiotropium, Trydonis significantly prolonged the time to first exacerbation (hazard ratio 0.80 and 0.84 respectively; p = 0.020 and 0.015 respectively), with no differences between Trydonis and the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (hazard ratio 1.06). 
0,84; p = 0,020 oz. 0,015), brez razlik med zdravilom Trydonis in trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija (razmerje tveganja 1,06).
Trydonis 87/5/9 micrograms pressurised inhalation beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium Inhalation use 
Trydonis 87/5/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij za inhaliranje
For glycopyrronium, the maximum plasma concentration was similar after administration of the fixed or extemporary combination, while the systemic exposure was slightly higher after administration of Trydonis than with the extemporary combination. 
Za glikopironij je bila največja koncentracija v plazmi podobna po dajanju fiksne kombinacije ali trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus glikopironija,
How to store Trydonis 
Shranjevanje zdravila Trydonis
The daily dose of Trydonis corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids. 
Ti učinki so bistveno manj verjetni med uporabo inhaliranih kortikosteroidov kot med uporabo peroralnih kortikosteroidov.
• if you have difficulty passing urine. 
• če imate težavo z očmi, imenovano glavkom z zaprtim zakotjem; • če imate težave z odvajanjem urina;
The long-term co-administration of Trydonis with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended (see section 4.4). 
niso preučili in se zato ne priporoča (glejte poglavje 4.4).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS ALUMINIUM CONTAINER 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
The combination of Trydonis with some other COPD medicines or medicines such as diuretics (medicines that make the body lose water, to treat heart disease or high blood pressure), can cause a sharp fall in your blood level of potassium. 
Kombinacija zdravila Trydonis z nekaterimi drugimi zdravili za KOPB ali zdravili, kot so npr. diuretiki (zdravili za odvajanje vode,
Therefore, your doctor may wish to measure the potassium levels in your blood from time to time. 
Zato vam bo zdravnik morda občasno spremljal koncentracijo kalija v krvi; • če imate katero od bolezni jeter ali ledvic;
• fungal infections of the throat or of the food pipe (oesophagus) 
• glivične okužbe žrela ali požiralnika;
• trembling 
Trydonis.
The exact way in which levetiracetam works is still unclear but it seems to interfere with a protein called synaptic vesicle protein 2A, which is found in the spaces between nerves and is involved in the release of chemical messengers from nerve cells. 
Natančen način delovanja levetiracetama še vedno ni pojasnjen, toda zdi se, da vpliva na beljakovino, imenovano sinaptični vezikularni protein 2A, ki se nahaja v prostoru med živčnimi celicami in zavira sproščanje kemičnih prenašalcev iz živčnih celic.
The European Commission granted a marketing authorisation valid throughout the European Union for Matever on 03 October 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Matever, veljavno po vsej Evropski uniji, odobrila dne 03. oktobra 2011.
This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear. 
To je vrsta epilepsije, pri kateri prevelika električna aktivnost na samo eni strani možganov povzroči simptome, kot so nenadni sunkoviti gibi enega dela telesa, motnje sluha, voha ali vida, odrevenelost ali nenaden občutek strahu.
What are the benefits and risks of Matever? 
Kakšne so koristi in tveganja, povezani z zdravilom Matever?
The full EPAR for Matever can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Matever je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
For more information about treatment with Matever, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Matever preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
It is available as tablets (250 mg, 500 mg, 750 mg and 1000 mg) and as a concentrate that is made up into a solution for infusion (drip into a vein, 100 mg/ml). 
Na voljo je v obliki tablet (250 mg, 500 mg, 750 mg in 1 000 mg) in v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije v veno, 100 mg/ml).
This means that Matever is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Keppra.
Lower doses are used in patients who have problems with their kidneys (such as older patients). 
Manjši odmerki se uporabljajo pri bolnikih, ki imajo težave z delovanjem ledvic (na primer starejši bolniki).
This is a summary of the European public assessment report (EPAR) for Matever. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Matever.
This helps Matever to stabilise electrical activity in the brain and prevent seizures. 
To omogoča zdravilu Matever, da stabilizira električno aktivnost v možganih in prepreči napade.
• primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). 
• primarno generaliziranih tonično-kloničnih napadov (daljših napadov, vključno z izgubo zavesti) pri bolnikih od 12. leta starosti dalje z idiopatsko generalizirano epilepsijo (vrsto epilepsije, za katero se domneva, da je genetskega izvora).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Matever. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Matever, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Matever tablets are swallowed with liquid. 
Tablete Matever je treba pogoltniti s tekočino.
Because Matever is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Matever generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
The Committee recommended that Matever be given marketing authorisation. 
Odbor je zato priporočil, da se za zdravilo Matever odobri dovoljenje za promet.
Matever can also be used as an add-on to other anti-epileptic medicines to treat: 
Zdravilo Matever se lahko uporablja kot dopolnilno zdravljenje k drugim zdravilom proti epilepsiji za zdravljenje:
The active substance in Matever, levetiracetam, is an anti-epileptic medicine. 
Zdravilna učinkovina v zdravilu Matever, levetiracetam, je zdravilo proti epilepsiji.
Other information about Matever 
Druge informacije o zdravilu Matever:
The daily dose can be increased up to 1500 mg twice a day. 
Dnevni odmerek se lahko poveča do največ 1 500 mg dvakrat na dan.
In patients aged between six months and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day. 
Pri otrocih od šestega meseca do 17. leta starosti, ki tehtajo manj kot 50 kg, je začetni odmerek 10 mg/kg telesne mase dvakrat dnevno, ki ga je mogoče povečati vse do 30 mg/kg telesne mase dvakrat dnevno.
Why has Matever been approved? 
Zakaj je bilo zdravilo Matever odobreno?
Because Matever is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra. 
Ker je zdravilo Matever generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Keppra.
Matever can be given as an infusion using the same doses at the same frequency when using the tablets or the oral solution is not possible. 
Zdravilo Matever se lahko daje kot infuzija v enakih odmerkih in enako pogosto, kadar uporaba tablet ali peroralne raztopine ni mogoča.
Matever is a medicine that contains the active substance levetiracetam. 
Matever je zdravilo, ki vsebuje zdravilno učinkovino levetiracetam.
Matever can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. 
Zdravilo Matever se lahko uporablja kot samostojno zdravilo pri bolnikih, starejših od 16 let, ki imajo na novo diagnosticirano epilepsijo, za zdravljenje napadov parcialnega izvora s sekundarno generalizacijo ali brez nje.
Therefore, the CHMP's view was that, as for Keppra, the benefit outweighs the identified risk. 
Zato je CHMP menil, da njegove koristi, tako kot pri referenčnem zdravilu Keppra, odtehtajo znana tveganja.
EPAR summary for the public levetiracetam 
Povzetek EPAR za javnost
Matever is a ‘generic medicine'. 
Zdravilo Matever je generično zdravilo.
When Matever is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day. 
Kadar se zdravilo Matever dodaja drugemu zdravilu proti epilepsiji, je začetni odmerek pri bolnikih, starejših od 12 let, ki tehtajo več kot 50 kg, 500 mg dvakrat na dan.
The CHMP concluded that, in accordance with EU requirements, Matever has been shown to have comparable quality and to be bioequivalent to Keppra. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Matever primerljivo raven kakovosti kot referenčno zdravilo Keppra ter da mu je biološko enakovredno.
• myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12 
• miokloničnih napadov (kratkih, krču podobnih sunkovitih gibov mišice ali skupine mišic) pri bolnikih z juvenilno mioklonično epilepsijo od starosti 12 let dalje;
How has Matever been studied? 
Kako je bilo zdravilo Matever raziskano?
What is Matever used for? 
Za kaj se zdravilo Matever uporablja?
What is Matever? 
Kaj je zdravilo Matever?
How is Matever used? 
Kako se zdravilo Matever uporablja?
When Matever is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day. 
Kadar se zdravilo Matever uporablja kot samostojno zdravilo, je začetni odmerek 250 mg dvakrat na dan, ki se dva tedna pozneje poveča na 500 mg dvakrat na dan. Odmerki se lahko glede na bolnikov odziv še naprej povečujejo v dvotedenskih razmakih do največjega odmerka 1 500 mg dvakrat na dan.
How does Matever work? 
Kako zdravilo Matever deluje?
This summary was last updated on 16 April 2009. 
Ta povzetek je bil nazadnje posodobljen dne 16 aprila 2009.
The vaccine also contains an ‘adjuvant' (mineral oil) to stimulate a better response. 
Cepivo vsebuje tudi „adjuvans“ (mineralno olje) za spodbujanje boljšega odziva.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against diseases. 
Cepiva delujejo tako, da „učijo“ imunski sistem (naravno obrambo telesa), kako se braniti pred boleznimi.
Swelling after the first vaccination normally resolves within 30 days, and may last at least 35 days following the second vaccination. 
Po prvem cepljenju oteklina običajno uplahne v 30 dneh in lahko traja najmanj 35 dni po drugem cepljenju.
Other information about Netvax: 
Druge informacije o zdravilu Netvax:
The vaccination schedule consists of two doses: the first dose is given at 10 to 14 weeks of age, and then a second dose is given four to 10 weeks after the first. 
Shemo cepljenja sestavljata dva odmerka: prvi odmerek se daje pri 10. do 14. tednu starosti, drugi pa štiri do 10 tednov po prvem odmerku.
The vaccine protected the chicks during the early period of life, when they are at greatest risk of the disease. 
Cepivo je zaščitilo piščance v zgodnjem obdobju življenja, ko je tveganje za razvoj bolezni največje.
If pain persists for more than 12 hours after examination, seek medical advice again. 
Če bolečina ne popusti po 12 urah po zdravniškem pregledu, se ponovno posvetujte z zdravnikom.
What benefit has Netvax shown during the studies? 
Kakšne koristi je zdravilo Netvax izkazalo med študijami?
Netvax is a vaccine. 
Zdravilo Netvax je cepivo.
The CVMP recommended that Netvax should be given a marketing authorisation. 
CVMP je priporočil, da se za zdravilo Netvax odobri dovoljenje za promet.
Vaccination causes swelling at the site of injection. 
Cepljenje povzroči oteklino na mestu injiciranja.
The studies showed that the vaccine is effective in stimulating the production of antibodies in chickens and in their eggs. 
Študije so pokazale, da je cepivo učinkovito pri spodbujanju proizvodnje protiteles pri kokoših in njihovih jajcih.
Netvax is used to reduce the number of deaths, and the incidence and severity of the disease. 
Zdravilo Netvax se uporablja za zmanjšanje števila poginov ter pojavnosti in resnosti bolezni.
Birds with the disease fail to thrive. 
Ptice s to boleznijo se ne razvijajo.
The effectiveness of Netvax has been studied in several trials under laboratory and field conditions in chickens and their chicks. 
Učinkovitost zdravila Netvax so raziskovali v številnih preskušanjih v laboratorijskih in terenskih razmerah pri kokoših in njihovih potomcih.
Accidental injection of Netvax can cause severe pain and swelling, particularly if it is accidentally injected into a joint or finger. 
Nenamerno injiciranje zdravila Netvax lahko povzroči hude bolečine in otekline, zlasti ob injiciranju v sklep ali prst.
The benefit-risk balance may be found in module 6 of this EPAR. 
Razmerje med koristmi in tveganji je na voljo v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
The European Commission granted a marketing authorisation valid throughout the European Union for Netvax to Intervet International B.V. on 16 April 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Netvax, veljavno po vsej Evropski uniji, odobrila družbi Intervet International B.V.
What is the risk associated with Netvax? 
Kakšna tveganja so povezana z zdravilom Netvax?
The studies compared chickens vaccinated with Netvax with birds that did not receive the vaccine. 
V študijah so primerjale kokoši, cepljene z zdravilom Netvax, s tistimi, ki cepiva niso prejele.
Necrotising enteritis is a disease that causes damage to the gut. 
Nekrotični enteritis je bolezen, ki poškoduje prebavni sistem.
The antibodies are transferred from the chicken to the chicks via the eggs. 
Protitelesa se prenašajo s kokoši na njihove potomce prek jajc.
Netvax is given by injection into the breast muscle. 
Zdravilo Netvax se injicira v prsno mišico.
The main measure of effectiveness was the production of protective antibodies against C. perfringens type A in the chickens' blood and in their eggs. 
Glavno merilo učinkovitosti je bila proizvodnja zaščitnih protiteles proti C. perfringens tipa A v krvi in jajcih kokoši.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NETVAX EPAR summary for the public 
EMEA/V/C/134 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) NETVAX Povzetek EPAR za javnost
Why has Netvax been approved? 
Zakaj je bilo zdravilo Netvax odobreno?
This second dose should be given at least six weeks before the hen will start to lay eggs. 
Drugi odmerek je treba dati najmanj šest tednov pred nesnostjo.
The hen can continue to pass on immunity to her chicks for almost a year after the end of vaccination. 
Kokoš lahko še skoraj eno leto po koncu cepljenja prenaša odpornost na svoje potomce.